Human immunodeficiency virus type 1 (HIV-1) (3, 32) , the etiological agent of AIDS (10) , can be isolated from both T cells and macrophages of infected individuals (13, 32) . HIV-1 replication in both cell types has been demonstrated in vivo, and infection of macrophages is thought to be an important pathogenic step in the induction of dementia and other central nervous system ailments often observed in AIDS patients (1, 12, 13, 18, 21, 22, 41) . Furthermore, HIV-1 can remain in a latent state in macrophages and this cell type might represent an important virus reservoir in the tissues of infected individuals. Selection of viruses with tropism for one cell type or the other often occurs in vitro, indicating that each HIV-1 strain is composed of a collection of microvariant genotypes with different biological features, such as the capability of infecting different target cells (2, 4, 8) . Both T cells and macrophages express the CD4 molecule, the major receptor for HIV-1 (6) . Several studies aimed to address the issue of HIV-1 macrophage tropism have revealed the existence of specific genetic determinants in the viral envelope which influence viral replication in human macrophages, including the HIV-1 V3 region (19, 31, 43, 45) . However, evidence is accumulating that macrophage tropism has multiple determinants, and it is likely that both cellular and viral factor(s) influence viral replication after entry. In addition to genes that are indispensable for viral replication, such as tat and rev, HIV-1 and its relatives, HIV-2 and simian immunodeficiency virus, carry other genes (i.e., vpr, vpu, vpx, vif, and nef), the function of which is still uncertain. Previous (9, 20, 29, 36, 37, 40) and the HIV-2/simian immunodeficiency virus Vpx protein positively influences viral growth in primary peripheral blood monocytes (16, 26, 42, 47) . More specifically, the HIV-2 vpr gene, which has a counterpart in HIV-1 (46) , has been shown to modulate viral replication in primary human macrophages (17) but not in T cells (7, 17, 40 Fig. 1 . Most of the synthesized phosphorothioate oligodeoxynucleotides are depicted in the lower part of the figure. Oligodeoxynucleotides 9 and 9a (antisense oligodeoxynucleotides 24 and 27 bases long, respectively) were targeted to the AUG of the HIV-1 Vpr mRNA. Their nucleotide sequence is highly conserved among different HIV-1 isolates and was derived from HIV-1MN (15, 33), a prevalent virus in the western world. The remaining antisense oligodeoxynucleotides (no. 1, 2, and 3) were 27 bases long and were derived from the DNA sequence of the HIV-1Ba-L isolate (12) . Oligodeoxynucleotides 9, 9a, and 1 overlap with the sequence encoding the C-terminal portion of the Vif protein (Fig. 1) . In contrast, oligodeoxynucleotides 2 and 3 were targeted at the genomic region presumably encoding only the Vpr protein (Fig. 1) . The control oligodeoxynucleotide no. 4 (sense) was derived from the complementary strand of no. 3, whereas the control oligodeoxynucleotides 10 and lOa were antisense as were no. 9 and 9a, respectively, but with opposite 5'-3' orientation. 5,
J. VIROL. (Fig.  2) , as often observed with primary macrophage cultures. The antisense phosphorothioate oligodeoxynucleotide 9, targeted at the initiation codon of the Vpr protein ( Fig. 1) , also inhibited viral replication approximately 60 to 80% at day 10 at both 10 and 20 ,uM, but this inhibitory effect was not maintained at 10 ,uM at day 15 (data not shown). However, when the size of the oligodeoxynucleotide 9 was increased to 27 bases (oligodeoxynucleotide 9a) the antiviral effect was observed also at 10 ,uM (Fig. 3) indicating the importance of size in the antiviral activity of this phosphorothioate oligodeoxynucleotide.
Interestingly, although phosphorothioate oligodeoxynucleotides 9 and 9a sequences overlap with the C terminus of the vif gene, which is required for viral infectivity in vitro (9, 20, 29, 34, 36, 37, 40) and in vivo (our unpublished results), it did not inhibit viral replication in macrophages to a higher degree than phosphorothioate oligodeoxynucleotides 2 or 3 ( Fig. 3) , which map exclusively within the vpr gene. It is possible that the interaction of phosphorothioate oligodeoxynucleotides 9 and 9a with the 3' of the Vif mRNA is not sufficient to induce a decrease in the Vif protein synthesis.
To assess whether the decreased viral expression observed in the cultures containing the control oligodeoxynucleotides was to be attributed to the non-sequence-specific effect of the phosphorothioate oligodeoxynucleotides (39) rather than to direct cellular toxicity, the viability of the cultured macrophages in the presence and absence of HIVlBa-L and the various phosphorothioate oligodeoxynucleotides was tested. As summarized in Tables 2 and 3, (25, 38) .
Antisense phosphorothioate oligodeoxynucleotides directed against the regulatory tat and rev genes have been tested and shown to interfere with HIV replication in both acute and chronic infection in vitro (14, 27, 28) . However, targeting other genes which might be involved in the late (24) , which is susceptible to HIVAlBa-L (data not shown).
These results confirm that vpr may be more important for replication of HIV-1 in macrophages than in T cells. Infection of macrophages is believed to represent an important pathogenic step for AIDS development, as suggested by the finding that the isolation of macrophage-tropic viruses is more frequent during the long asymptomatic period (35) . Additionally, we found that abrogation of the vpr function in an infectious molecular clone of HIV-2 rendered the virus incapable of establishing persistent infection in rhesus macaques (unpublished results). Thus, the development of specific antiviral inhibitors which interfere with HIV replication in macrophages might be beneficial for the prevention of AIDS development in infected individuals. Furthermore, antiviral therapy based on a combination of antisense oligodeoxynucleotides targeted to different viral genes might help to minimize the problem of viral escape due to genetic variations.
